Where can patients receive this treatment?

It is currently in the confirmatory clinical trial phase at selected medical institutions in Japan. It will become available nationwide following regulatory approval, targeted after 2026.

Is the LIPUS treatment painful?

Not at all. The ultrasound output is at the same level as diagnostic echo devices, so patients feel no pain or stimulation and do not require anesthesia.

Is LIPUS effective for conditions other than Alzheimer's?

The company is also developing applications for severe angina, arrhythmia, and other conditions that benefit from improved microcirculation and angiogenesis.

AI News NQ Analysis

Soundwave Innovation Secures 2.65 Billion Yen in Series C Funding to Complete Clinical Trials for LIPUS-Brain, an Alzheimer's Treatment Device

NQ Score 47/100

N1 Content Completeness 5

AI Summary (NQ-processed)

Soundwave Innovation (SWI) has raised approximately 2.65 billion yen in a Series C round to complete the confirmatory clinical trial of its 'LIPUS-Brain' medical device for treating early-stage Alzheimer's disease. The funding involves domestic and international investors including Fiducia, Sumitomo Heavy Industries, and iGlobe Partners. SWI aims to complete the trial in 2026 and proceed with regulatory approval application through its partner, Sumitomo Heavy Industries.

AI Analysis

Frequently Asked Questions

Q: Where can patients receive this treatment?: A: It is currently in the confirmatory clinical trial phase at selected medical institutions in Japan. It will become available nationwide following regulatory approval, targeted after 2026.
Q: Is the LIPUS treatment painful?: A: Not at all. The ultrasound output is at the same level as diagnostic echo devices, so patients feel no pain or stimulation and do not require anesthesia.
Q: Is LIPUS effective for conditions other than Alzheimer's?: A: The company is also developing applications for severe angina, arrhythmia, and other conditions that benefit from improved microcirculation and angiogenesis.